Pure Global
NCT06264440

A Study to Assess the Potential for Gastric-pH Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy Participants

A Phase 1, Open-Label, Crossover Study to Assess the Potential for Gastric pH-Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy Participants
Biogen·Phase 1·ClinicalTrials.gov·drugRecruitment Completed
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Healthy Volunteer
Drug/Device/Intervention
BIIB122
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Biogen
Location
Austin, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
Feb 12, 2024
End date
May 07, 2024
Enrollment
18 participants
Primary outcome

Maximum Observed Concentration (Cmax) of BIIB122,Area Under the Concentration-Time Curve From Time Zero to Time of the Last Measurable Concentration (AUClast) of BIIB122,Area Under the Concentration-Time Curve From Time Zero to Infinity (AUCinf) of BIIB122

Summary

The primary objective of the study is to evaluate the effects of a proton pump inhibitor
 (PPI) [rabeprazole] on BIIB122 pharmacokinetics (PK) after a single dose in healthy
 participants. The secondary objective of the study is to evaluate the safety and tolerability
 of BIIB122, with and without a PPI (rabeprazole), after a single dose in healthy
 participants.

ICD-10 classifications
Healthy person accompanying sick personRoutine general health check-up of armed forcesPersons encountering health services in other circumstancesPersons encountering health services in other circumstancesPerson encountering health services in unspecified circumstances
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06264440
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06264440 through Pure Global AI's free database. This Phase 1 trial is sponsored by Biogen and is currently Recruitment Completed. The study focuses on Healthy Volunteer. Target enrollment is 18 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.